Exome Sequencing Identifies Germline Variants in DIS3 in Familial Multiple Myeloma

Lionetti M, Barbieri M, Todoerti K, Agnelli L, Fabris S, Tonon G . A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget. 2015; 6(28):26129-41. PMC: 4694891. DOI: 10.18632/oncotarget.4674. View

Szczepinska T, Kalisiak K, Tomecki R, Labno A, Borowski L, Kulinski T . DIS3 shapes the RNA polymerase II transcriptome in humans by degrading a variety of unwanted transcripts. Genome Res. 2015; 25(11):1622-33. PMC: 4617959. DOI: 10.1101/gr.189597.115. View

Morgan G, Davies F, Linet M . Myeloma aetiology and epidemiology. Biomed Pharmacother. 2002; 56(5):223-34. DOI: 10.1016/s0753-3322(02)00194-4. View

Weissbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M . The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2014; 169(1):57-70. DOI: 10.1111/bjh.13256. View

Morgan G, Johnson D, Weinhold N, Goldschmidt H, Landgren O, Lynch H . Inherited genetic susceptibility to multiple myeloma. Leukemia. 2013; 28(3):518-24. DOI: 10.1038/leu.2013.344. View

Waller R, Darlington T, Wei X, Madsen M, Thomas A, Curtin K . Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet. 2018; 14(2):e1007111. PMC: 5794067. DOI: 10.1371/journal.pgen.1007111. View

Halvarsson B, Wihlborg A, Ali M, Lemonakis K, Johnsson E, Niroula A . Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2018; 1(10):619-623. PMC: 5728350. DOI: 10.1182/bloodadvances.2016003111. View

Lohr J, Stojanov P, Carter S, Cruz-Gordillo P, Lawrence M, Auclair D . Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25(1):91-101. PMC: 4241387. DOI: 10.1016/j.ccr.2013.12.015. View

Bolli N, Avet-Loiseau H, Wedge D, Van Loo P, Alexandrov L, Martincorena I . Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997. PMC: 3905727. DOI: 10.1038/ncomms3997. View

10.

Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A . Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-72. PMC: 3560292. DOI: 10.1038/nature09837. View

11.

Wei X, Calvo-Vidal M, Chen S, Wu G, Revuelta M, Sun J . Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018; 78(10):2747-2759. PMC: 5955848. DOI: 10.1158/0008-5472.CAN-17-1900. View

12.

Went M, Sud A, Forsti A, Halvarsson B, Weinhold N, Kimber S . Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018; 9(1):3707. PMC: 6137048. DOI: 10.1038/s41467-018-04989-w. View

13.

Robinson S, Oliver A, Chevassut T, Newbury S . The 3' to 5' Exoribonuclease DIS3: From Structure and Mechanisms to Biological Functions and Role in Human Disease. Biomolecules. 2015; 5(3):1515-39. PMC: 4598762. DOI: 10.3390/biom5031515. View

14.

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597. PMC: 6097138. DOI: 10.1182/blood-2018-03-840132. View

15.

Dziembowski A, Lorentzen E, Conti E, Seraphin B . A single subunit, Dis3, is essentially responsible for yeast exosome core activity. Nat Struct Mol Biol. 2006; 14(1):15-22. DOI: 10.1038/nsmb1184. View

16.

Weiss B, Abadie J, Verma P, Howard R, Kuehl W . A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22):5418-22. PMC: 2689043. DOI: 10.1182/blood-2008-12-195008. View